Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.

被引：0
|
作者：
Yen, Chia Jui
Oh, Do-Youn
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Li, Jin
Yang, Lin
Yasui, Hisateru
Yabusaki, Hiroshi
Lam, Ka On
Yamaguchi, Kensei
Yeh, Kun-Huei
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
机构：
[1] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[4] Univ Ulsan, Coll Med, Coll Med, Seoul, South Korea
[5] Samsung Med Ctr, Seoul, South Korea
[6] Tongji Univ, Sch Med, Shanghai East Hosp, Shanghai, Peoples R China
[7] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[8] Kobe City Med Ctr Gen Hosp, Kobe, Japan
[9] Niigata Canc Ctr Hosp, Niigata, Japan
[10] Queen Mary Hosp, Hong Kong, Peoples R China
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] Natl Taiwan Univ, Natl Taiwan Univ Hosp & Grad Inst Oncol, Coll Med, Taipei, Taiwan
[13] Merck & Co Inc, Rahway, NJ USA
[14] MSD France, Courbevoie 92, France
[15] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Coll Med, Seoul 120752, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.464
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：464 / 464
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
    Oh, D-Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Li, J.
    Luo, S.
    Pan, H.
    Qu, Y.
    Lu, J.
    Yang, L.
    Yasui, H.
    Yabusaki, H.
    Yen, C. J.
    Chan, W. W. L.
    Yamaguchi, K.
    Yeh, K-H.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1526
  • [2] KEYNOTE-859 update: Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
    Ryu, M. H.
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Yanez
    Bai, Y.
    Lee, J.
    Herrero, F. Rivera
    Alves, G. V.
    Garrido, M.
    Shiu, K-K.
    Gonzalez Fernandez, M.
    Li, J.
    Lowery, M. A.
    Cil, T.
    Cruz, F.
    Oh, D-Y.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Qin, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1473 - S1474
  • [3] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.
    Rha, Sun Young
    Lee, Jeeyun
    Ryu, Min-Hee
    Yin, Lina
    Leconte, Pierre
    Bhagia, Pooja
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 428 - 428
  • [4] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
    Rha, Sun Young
    Wyrwicz, Lucjan S.
    Weber, Patricio Eduardo Yanez
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve Aine
    Cil, Timucin
    Cruz, Felipe Melo
    Oh, Do-Youn
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
    Wyrwicz, L.
    Oh, D.
    Weber, P.
    Bai, Y.
    Ryu, M.
    Lee, J.
    Rivera, F.
    Alves, G. Vasconcelos
    Garrido, M.
    Shiu, K.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Rha, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S181 - S181
  • [6] Q-TWiST analysis of pembrolizumab or placebo plus chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in KEYNOTE-859.
    Wyrwicz, Lucjan
    Kalampoki, Vasiliki
    Valderrama, Adriana
    Ramakrishnan, Karthik
    Young, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [7] Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
    Tabernero, Josep
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Janjigian, Yelena Y.
    Bhagia, Pooja
    Li Kan
    Adelberg, David E.
    Kui, Qin Shu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [8] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [9] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [10] KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
    Tabernero, Josep
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Janjigian, Yelena Yuriy
    Bhagia, Pooja
    Li, Kan
    Adelberg, David
    Qin, Shu Kui
    FUTURE ONCOLOGY, 2021, 17 (22) : 2847 - 2855
12345